|
1
|
Zhang S, Guo H, Zhang D, Zhang W, Zhao X,
Ren Z and Sun B: Microcirculation patterns in different stages of
melanoma growth. Oncol Rep. 15:15–20. 2006.PubMed/NCBI
|
|
2
|
Chen J, Wang Y, Wu M, Yu K, Liu J and
Chang J: Vasculogenic mimicry triggers early recidivation and
resistance to adjuvant therapy in esophageal cancer. BMC Cancer.
24:11322024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miao K, Liu W, Xu J, Qian Z and Zhang Q:
Harnessing the power of traditional Chinese medicine monomers and
compound prescriptions to boost cancer immunotherapy. Front
Immunol. 14:12772432023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
5
|
Chen JG, Zhang YH, Lu JH and Kensler TW:
Liver cancer etiology: Old issues and new perspectives. Curr Oncol
Rep. 26:1452–1468. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng N, Zhang S, Wu W, Zhang N and Wang
J: Regulatory mechanisms and therapeutic targeting of vasculogenic
mimicry in hepatocellular carcinoma. Pharmacol Res. 166:1055072021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Duan X, Zou H, Yang J, Liu S, Xu T and
Ding J: Melittin-incorporated nanomedicines for enhanced cancer
immunotherapy. J Control Release. 375:285–299. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Q, Lin W, Yin Z, Zou Y, Liang S, Ruan
S, Chen P, Li S, Shu Q, Cheng B and Ling C: Melittin inhibits
hypoxia-induced vasculogenic mimicry formation and
epithelial-mesenchymal transition through suppression of HIF-1α/Akt
pathway in liver cancer. Evid Based Complement Alternat Med.
2019:96029352019.PubMed/NCBI
|
|
9
|
Song X, Tan L, Wang M, Ren C, Guo C, Yang
B, Ren Y, Cao Z, Li Y and Pei J: Myricetin: A review of the most
recent research. Biomed Pharmacother. 134:1110172021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang M, Ren S, Bi Z, Zhang L, Cui M, Sun
R, Bao J, Gao D, Yang B, Li X, et al: Myricetin reverses
epithelial-endothelial transition and inhibits vasculogenic mimicry
and angiogenesis of hepatocellular carcinoma by directly targeting
PAR1. Phytother Res. 36:1807–1821. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiao T, Zhang Q, Zong S, Zhong WL, Qin Y,
Bi Z, Chen S, Liu HJ, Wei JJ, et al: Protease-activated receptor-1
(PAR1) promotes epithelial-endothelial transition through Twist1 in
hepatocellular carcinoma. J Exp Clin Cancer Res. 37:1852018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang X, Zhang JG, Mu W, Zhou HM, Liu GL
and Li Q: The role of daurisoline treatment in hepatocellular
carcinoma: Inhibiting vasculogenic mimicry formation and enhancing
sensitivity to sorafenib. Phytomedicine. 92:1537402021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Djati MS, Habibu H, Jatiatmaja NA and
Rifa'I M: Tapak liman (Elephantopus scaber L.)
extract-induced CD4+ and CD8+ differentiation from hematopoietic
stem cells and progenitor cell proliferation in mice (Mus
musculus L). AIP Conf Proc. Nov 29–2017.(Epub ahead of print).
View Article : Google Scholar
|
|
14
|
Wang J, Liao C, Huang G, Li W, Huang Y,
Liao Z and Huang S: Effect of Elephantopus scaber L. extract
on vasculogenic mimicry of hepatocellular carcinoma. J Chin Clin
Pharmacol. 38:652–656. 2022.(In Chinese).
|
|
15
|
Feng X, Yin Z, Ou S, Chu Z, Feng J, Luo Y,
Hu Y, Liu Y, Jiang W, Wang X and Wang H: The anti-tumor effects of
Celastrus orbiculatus Thunb. and its monomer composition: A review.
J Ethnopharmacol. 310:1163632023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen J, Dai SY, Wu S, Wu MK, Yu KK, Liu
JC, Chang JY and Liu YQ: COE targets EphA2 to inhibit vasculogenic
mimicry formation induced by hypoxia in hepatocellular carcinoma.
Front Pharmacol. 15:14214702024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hsu JL, Leu WJ, Hsu LC, Hsieh CH and Guh
JH: Doxazosin inhibits vasculogenic mimicry in human non-small cell
lung cancer through inhibition of the VEGF-A/VE-cadherin/mTOR/MMP
pathway. Oncol Lett. 27:1702024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mao C, Zhang J, Yang C, Mei L, Feng Y, Dai
F, Huang Y, Xiao H and Deng B: BCAR1 facilitates the survival of
lung adenocarcinoma cells by augmenting the unfolded protein
response, autophagy, and the formation of vasculogenic mimicry.
Biochim Biophys Acta Mol Basis Dis. 1871:1675582025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lei C, Yu Y, Zhu Y, Li Y, Ma C, Ding L,
Han L and Zhang H: The most recent progress of baicalein in its
anti-neoplastic effects and mechanisms. Biomed Pharmacother.
176:1168622024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Z, Nong L, Chen M, Gu X, Zhao W, Liu
M and Cheng W: Baicalein suppresses vasculogenic mimicry through
inhibiting RhoA/ROCK expression in lung cancer A549 cell line. Acta
Biochim Biophys Sin (Shanghai). 52:1007–1015. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiao H, Xu X, Du L, Li X, Zhao H, Wang Z,
Zhao L, Yang Z, Zhang S, Yang Y and Wang C: Lycorine and organ
protection: Review of its potential effects and molecular
mechanisms. Phytomedicine. 104:1542662022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Z, Xiang S, Qi J, Wei Y, Zhang M, Yao
J, Zhang T, Meng M, Wang X and Zhou Q: Correction of the tumor
suppressor Salvador homolog-1 deficiency in tumors by lycorine as a
new strategy in lung cancer therapy. Cell Death Dis. 11:3872020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang W, Li M, Wang L, Chen L and Goh BC:
Curcumin in cancer therapy: Exploring molecular mechanisms and
overcoming clinical challenges. Cancer Lett. 570:2163322023.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
An Q, Shi CX, Guo H, Xie SM, Yang YY, Liu
YN, Liu ZH, Zhou CZ and Niu FJ: Development and characterization of
octreotide-modified curcumin plus docetaxel micelles for potential
treatment of non-small-cell lung cancer. Pharm Dev Technol.
24:1164–1174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin J, Wang Q, Zhou S, Xu S and Yao K:
Tetramethylpyrazine: A review on its mechanisms and functions.
Biomed Pharmacother. 150:1130052022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bin Liu, Meng Li, Jie He, Xiaoru Yan and
Zhang P: Effect of tetramethylpyrazine on vascular mimicry of A549
caner stem-like cell under hypoxia environment. Chin J Exp Tradit
Med Formulae. 28:64–70. 2022.(In Chinese).
|
|
27
|
Dai X, Zhang X, Chen W, Chen Y, Zhang Q,
Mo S and Lu J: Dihydroartemisinin: A potential natural anticancer
drug. Int J Biol Sci. 17:603–622. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bingqi Hu, Jing Zhou, Junfeng Huang and
Chen L: A preliminary study of dihydroartemisinin inhibiting
migration invasion and vasculogenic mimicry of non-small cell lung
cancer cells. An Hui Yi Ke Da Xue. 58:766–771. 2023.(In
Chinese).
|
|
29
|
Jin L, Chen C, Huang L, Bu L, Zhang L and
Yang Q: Salvianolic acid A blocks vasculogenic mimicry formation in
human non-small cell lung cancer via PI3K/Akt/mTOR signalling. Clin
Exp Pharmacol Physiol. 48:508–514. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Si L and Lai Y: Pharmacological mechanisms
by which baicalin ameliorates cardiovascular disease. Front
Pharmacol. 15:14159712024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rahman M, Afzal O, Ullah SNMN, Alshahrani
MY, Alkhathami AG, Altamimi ASA, Almujri SS, Almalki WH, Shorog EM,
Alossaimi MA, et al: Nanomedicine-based drug-targeting in breast
cancer: Pharmacokinetics, clinical progress and challenges. ACS
Omega. 8:48625–48649. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He X, Lan H, Jin K and Liu F: Can
immunotherapy reinforce chemotherapy efficacy? a new perspective on
colorectal cancer treatment. Front Immunol. 14:12377642023.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Choi HY and Chang JE: Targeted therapy for
cancers: From ongoing clinical trials to FDA-Approved drugs. Int J
Mol Sci. 24:136182023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Léna H, Greillier L, Cropet C, Bylicki O,
Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond
P, Geier M, et al: Nivolumab plus ipilimumab versus
carboplatin-based doublet as first-line treatment for patients with
advanced non-small-cell lung cancer aged ≥70 years or with an ECOG
performance status of 2 (GFPC 08-2015 ENERGY): A randomised,
open-label, phase 3 study. Lancet Respir Med. 13:141–152. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Randall LM and Monk BJ: Bevacizumab
toxicities and their management in ovarian cancer. Gynecol Oncol.
117:497–504. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Walia GK, Kinra P and Akal RS: Potential
for tumor aggressiveness and its association with vasculogenic
mimicry marker in colorectal carcinomas in Indian population- A
tertiary care hospital level study. Indian J Pathol Microbiol.
68:261–266. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang H, Chen L, Sun X, Yang Q, Wan L and
Guo C: Matrine: A promising natural product with various
pharmacological activities. Front Pharmacol. 11:5882020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Peng X, Zhou D, Wang X, Hu Z, Yan Y and
Huang J: Matrine suppresses proliferation and invasion of SGC7901
cells through Inactivation of PI3K/Akt/uPA pathway. Ann Clin Lab
Sci. 46:457–462. 2016.PubMed/NCBI
|
|
40
|
Du Q, Lin Y, Ding C, Wu L, Xu Y and Feng
Q: Pharmacological activity of matrine in inhibiting colon cancer
cells VM formation, proliferation, and invasion by downregulating
claudin-9 mediated EMT process and MAPK signaling pathway. Drug Des
Devel Ther. 17:2787–2804. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xiong X, Tang N, Lai X, Zhang J, Wen W, Li
X, Li A, Wu Y and Liu Z: Insights Into Amentoflavone: A natural
multifunctional biflavonoid. Front Pharmacol. 12:7687082021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feng N, Wang P, He M and Liu J: Effects of
Amentoflavone modulating HIF-1α/VEGF signalling pathway on
proliferation, apoptosis and angiogenic mimicry in colon cancer
cells. Chin J Gerontol. 45:701–707. 2025.(In Chinese).
|
|
43
|
Tan R, Li L and Luo D: Effectsofdel
phinidinonthebiolo gicalbehaviorandvasculo genic mimicr yformation
ofcoloncancercellsb yre gulatin gtheRhoA /ROCKsi gnalin gpathw.
Shaanxi Med J. 53:1468–1473. 2024.(In Chinese).
|
|
44
|
Lin L, Liu Y, Tang R, Ding S, Lin H and Li
H: Evodiamine: A extremely potential drug development candidate of
alkaloids from Evodia rutaecarpa. Int J Nanomedicine. 19:9843–9870.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zeng D, Zhou P, Jiang R, Li XP, Huang SY,
Li DY, Li GL, Li LS, Zhao S, Hu L, et al: Evodiamine inhibits
vasculogenic mimicry in HCT116 cells by suppressing
hypoxia-inducible factor 1-alpha-mediated angiogenesis. Anticancer
Drugs. 32:314–322. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mokadem I, Dijksterhuis WPM, Van Putten M,
Heuthorst L, de Vos-Geelen JM, Haj Mohammad N, Nieuwenhuijzen GAP,
van Laarhoven HWM and Verhoeven RHA: Recurrence after preoperative
chemotherapy and surgery for gastric adenocarcinoma: A multicenter
study. Gastric Cancer. 22:1263–1273. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ramos A, Sadeghi S and Tabatabaeian H:
Battling chemoresistance in cancer: Root causes and strategies to
uproot them. Int J Mol Sci. 22:94512021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Farkhondeh T, Pourbagher-Shahri AM,
Azimi-Nezhad M, Forouzanfar F, Brockmueller A, Ashrafizadeh M,
Talebi M, Shakibaei M and Samarghandian S: Roles of Nrf2 in gastric
cancer: Targeting for therapeutic strategies. Molecules.
26:31572021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Montagnani F, Turrisi G, Marinozzi C,
Aliberti C and Fiorentini G: Effectiveness and safety of
oxaliplatin compared to cisplatin for advanced, unresectable
gastric cancer: A systematic review and meta-analysis. Gastric
Cancer. 14:50–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim HS, Won YJ, Shim JH, Kim HJ, Kim BS
and Hong HN: Role of EphA2-PI3K signaling in vasculogenic mimicry
induced by cancer-associated fibroblasts in gastric cancer cells.
Oncol Lett. 18:3031–3038. 2019.PubMed/NCBI
|
|
51
|
Zang M, Hou J, Huang Y, Wang J, Ding X,
Zhang B, Wang Y, Xuan Y and Zhou Y: Crocetin suppresses
angiogenesis and metastasis through inhibiting sonic hedgehog
signaling pathway in gastric cancer. Biochem Biophys Res Commun.
576:86–92. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang H, Ding Q, Zhou H, Huang C, Liu G,
Zhao X, Cheng Z and You X: Dihydroartemisinin inhibited
vasculogenic mimicry in gastric cancer through the FGF2/FGFR1
signaling pathway. Phytomedicine. 134:1559622024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lun Han and Yanfei Ma: Effects of
formononetin on proliferation and apoptosis of gastric cancer cells
and tumor vasculogenic mimicry by regulating HIF-1α/VEGF signaling
pathway. Int J Dig Dis. 43:297–303. 2023.
|
|
54
|
Nakhjavani M, Smith E, Townsend AR, Price
TJ and Hardingham JE: Anti-angiogenic properties of ginsenoside
Rg3. Molecules. 25:49052020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huatinng Li and Youwei Tang: Ginsenoside
Rg3 suppresses the formation of vasculogenic mimicry of gastric
cancer SGC7901 cells by inhibiting Wnt/β-catenin pathway in vitro.
Chin J Cancer Biother. 26:518–523. 2019.(In Chinese).
|
|
56
|
Yang P, Zhang Q, Shen H, Bai X, Liu P and
Zhang T: Research progress on the protective effects of aucubin in
neurological diseases. Pharm Biol. 60:1088–1094. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Song M, Zhou X, Liu J, Hu W, Zhang M and
Zheng X: Effects of aucubin on epithelial mesenchymal transition
and vasculogenic mimicry in gastric cancer MGC803 cells by
regulating the RhoA/ROCK signaling pathway. Chin J Cancer Biother.
31:365–370. 2024.(In Chinese).
|
|
58
|
Sun B, Zhou L, Wang X, Lv Y, Zhang H, Tu J
and Feng H: Effectsof jaceosidinon proliferation,
apoptosisandvasculo genicmimicr y ofgastriccancercellsa. Shaanxi
Med J. 53:1463–1467. 2024.(In Chinese).
|
|
59
|
Zhang D, Wang W, Zhou H, Su L, Han X,
Zhang X, Han W, Wang Y and Xue X: ANXA1: An important independent
prognostic factor and molecular target in glioma. Front Genet.
13:8515052022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ahmed R, Oborski MJ, Hwang M, Lieberman FS
and Mountz JM: Malignant gliomas: Current perspectives in
diagnosis, treatment, and early response assessment using advanced
quantitative imaging methods. Cancer Manag Res. 6:149–170.
2014.PubMed/NCBI
|
|
61
|
Nabors LB, Portnow J, Ahluwalia M,
Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW,
Fabiano AJ, et al: Central nervous system cancers, version 3.2020,
NCCN clinical practice guidelines in oncology. J Natl Compr Cancer
Netw. 18:1537–1570. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liguori GL: Challenges and promise for
glioblastoma treatment through extracellular vesicle inquiry.
Cells. 13:3362024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zeng Z, Chen Y, Geng X, Zhang Y, Wen X,
Yan Q, Wang T, Ling C, Xu Y, Duan J, et al: NcRNAs: Multi-angle
participation in the regulation of glioma chemotherapy resistance
(Review). Int J Oncol. 60:762022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen YS and Chen ZP: Vasculogenic mimicry:
A novel target for glioma therapy. Chin J Cancer. 33:74–79. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li X, Shi L, Li Y and Li Q, Duan X, Wang Y
and Li Q: The enhanced treatment efficacy of invasive brain glioma
by dual-targeted artemether plus paclitaxel micelles. Artif Cells
Nanomed Biotechnol. 48:983–996. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chen Z, Ding W, Yang X, Lu T and Liu Y:
Isoliquiritigenin, a potential therapeutic agent for treatment of
inflammation-associated diseases. J Ethnopharmacol. 318:1170592024.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sun QH, Li ZY, Sun JJ, Liang SL, Li H and
LE LM: Research advances in isoliquiritigenin against glioma.
Journal of International Neurology and Neurosurgery. 49:89–92.
2022.(In Chinese).
|
|
68
|
Van Der Hoorn A, Yan JL, Larkin TJ,
Boonzaier NR, Matys T and Price SJ: Posttreatment apparent
diffusion coefficient changes in the periresectional area in
patients with glioblastoma. World Neurosurg. 92:159–165. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Oronsky B, Reid TR, Oronsky A, Sandhu N
and Knox SJ: A review of newly diagnosed glioblastoma. Front Oncol.
10:5740122021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Brown NF, Ottaviani D, Tazare J, Gregson
J, Kitchen N, Brandner S, Fersht N and Mulholland P: Survival
outcomes and prognostic factors in glioblastoma. Cancers (Basel).
14:31612022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Min P, Li Y, Wang C, Fan J, Liu S, Chen X,
Tang Y, Han F, Zhang A and Feng L: Cyclopeptide moroidin inhibits
vasculogenic mimicry formed by glioblastoma cells via regulating
β-catenin activation and EMT pathways. J Biomed Res. 38:322–333.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Campanile M, Cuomo O, Brancaccio P,
Vinciguerra A, Casamassa A, Pastorino O, Volpicelli F, Gentile MT,
Amoroso S, Annunziato L, et al: Ruta graveolens water
extract (RGWE) ameliorates ischemic damage and improves
neurological deficits in a rat model of transient focal brain
ischemia. Biomed Pharmacother. 154:1135872022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Camerino I, Franco P, Bajetto A, Thellung
S, Florio T, Stoppelli MP and Colucci-D'Amato L: Ruta
graveolens, but not Rutin, inhibits survival, migration,
invasion, and vasculogenic mimicry of glioblastoma cells. Int J Mol
Sci. 25:117892024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Gao B, Wang MD, Li Y and Huang F: Risk
stratification system and web-based nomogram constructed for
predicting the overall survival of primary osteosarcoma patients
after surgical resection. Front Public Health. 10:9495002022.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lilienthal I and Herold N: Targeting
molecular mechanisms underlying treatment efficacy and resistance
in osteosarcoma: A review of current and future strategies. Int J
Mol Sci. 21:68852020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shah A, Cardoso FN, Souza F, Montreuil J,
Pretell-Mazzini J, Temple HT, Hornicek F, Crawford B and Subhawong
TK: Failure modes in orthopedic oncologic reconstructive surgery: A
review of imaging findings and failure rates. Curr Oncol.
31:6245–6266. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Yan L, Li R, Li D, Zhu Y, Lv Z and Wang B:
Development of a novel vasculogenic mimicry-associated gene
signature for the prognostic assessment of osteosarcoma patients.
Clin Transl Oncol. 25:3501–3518. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ke F, Zhang R, Chen R, Guo X, Song C, Gao
X, Zeng F and Liu Q: The role of Rhizoma Paridis saponins on
anti-cancer: The potential mechanism and molecular targets.
Heliyon. 10:e373232024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yao N, Zhou J, Jiang Y, Jin Q, Zhu H,
Zhang J and Li Z: Rhizoma Paridis saponins suppresses vasculogenic
mimicry formation and metastasis in osteosarcoma through regulating
miR-520d-3p/MIG-7 axis. J Pharmacol Sci. 150:180–190. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hong Fang, Qun Zhang and Longbang Chen:
The Effects of Curcumin on Vasculogenic Mimicry in Vitro of Sarcoma
Cells and Its Mechanism. Western J Trad Chin Med. 33:21–25.
2020.(In Chinese).
|
|
81
|
Ke Ren, Jing Zhou, Zhenlin Li, Shihui
Qian, He Li and Chen Wang: Effects of Paris polyphylla
ethanol extract on human osteosarcoma and its mechanism. Chin Trad
Herbal Drugs. 50:120–128. 2019.(In Chinese).
|
|
82
|
Bilmin K, Synoradzki KJ, Czarnecka AM,
Spałek MJ, Kujawska T, Solnik M, Merks P, Toro MD, Rejdak R and
Fiedorowicz M: New perspectives for eye-sparing treatment
strategies in primary uveal melanoma. Cancers (Basel). 14:1342021.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Bai H, Bosch JJ and Heindl LM: Current
management of uveal melanoma: A review. Clin Exp Ophthalmol.
51:484–494. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sabazade S, Gill V, Herrspiegel C and
Stålhammar G: Vasculogenic mimicry correlates to presenting
symptoms and mortality in uveal melanoma. J Cancer Res Clin Oncol.
148:587–597. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yuan Y, Geng B, Xu X, Zhao H, Bai J, Dou
Z, Jia S, Yu X and Luo W: Dual VEGF/PDGF knockdown suppresses
vasculogenic mimicry formation in choroidal melanoma cells via the
Wnt5a/β-catenin/AKT signaling pathway. Acta Histochem.
124:1518422022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Liu X, Cai Y, Zhang Y, Zhang H, Tian S,
Gong Y, Song Q, Chen X, Ma X, Wen Y, et al: Artesunate: A potential
drug for the prevention and treatment from hepatitis to
hepatocellular carcinoma. Pharmacol Res. 210:1075262024. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ma QY, Xu XY, Zhu YZ, Yao NN, Liu YC, Gao
XD, Zhang Q and Luo WJ: Artesunate inhibits vasculogenic mimicry in
choroidal melanoma through HIF-1α/ VEGF/PDGF pathway. Acta
Histochem. 126:1521742024. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Geng B, Zhu Y, Yuan Y, Bai J, Dou Z, Sui A
and Luo W: Artesunate Suppresses Choroidal Melanoma Vasculogenic
Mimicry Formation and Angiogenesis via the Wnt/CaMKII Signaling
Axis. Front Oncol. 11:7146462021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Li JX, Zhang J, Wei CX, Zhang H, Pei C,
Zhao F and Cai ZP: Effect of Artesunate on Experimental Choroidal
Neovascularization and Expression of HIF-1α and VEGF. Chinese
Journal of Experimental Traditional Medical Formulae. 27:83–89.
2021.(In Chinese).
|
|
90
|
Ma QY, Liu YC, Zhang Q, Yi WD, Sun Y, Gao
XD, Zhao XT, Wang HW, Lei K and Luo WJ: Integrating network
pharmacology, molecular docking and experimental verification to
reveal the mechanism of artesunate in inhibiting choroidal
melanoma. Front Pharmacol. 14483812024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhu M, Sun Y, Su Y, Guan W, Wang Y, Han J,
Wang S, Yang B, Wang Q and Kuang H: Luteolin: A promising
multifunctional natural flavonoid for human diseases. Phytother
Res. 38:3417–3443. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Chen YF, Wu S, Li X, Chen M and Liao HF:
Luteolin suppresses three angiogenesis modes and cell interaction
in uveal melanoma in vitro. Curr Eye Res. 47:1590–1599. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Shi M, Wu W, Luo H, Yu J and Liao H:
Inhibitory effects of luteolin on vasculogenic mimicry in human
choroidal melanoma cell line C918. Recent Adv Ophthalmol.
40:731–735. 2020.
|
|
94
|
Li X, Chen M, Lei X, Huang M, Ye W, Zhang
R and Zhang D: Luteolin inhibits angiogenesis by blocking Gas6/Axl
signaling pathway. Int J Oncol. 51:677–685. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Wu S, Xu J, Ma Y, Liang G, Wang J and Sun
T: Advances in the mechanism of CDK4/6 inhibitor resistance in
HR+/HER2- breast cancer. Ther Adv Med Oncol.
16:175883592412824992024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wang Y and Minden A: Current molecular
combination therapies used for the treatment of breast cancer. Int
J Mol Sci. 23:110462022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Morales-Guadarrama G, García-Becerra R,
Méndez-Pérez EA, García-Quiroz J, Avila E and Díaz L: Vasculogenic
mimicry in breast cancer: Clinical relevance and drivers. Cells.
10:17582021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Xu MR, Wei PF, Suo MZ, Hu Y, Ding W, Su L,
Zhu YD, Song WJ, Tang GH, Zhang M and Li P: Brucine suppresses
vasculogenic mimicry in human triple-negative breast cancer cell
line MDA-MB-231. Biomed Res Int. 2019:65432302019.PubMed/NCBI
|
|
99
|
Zhang M, Meng M, Liu Y, Qi J, Zhao Z, Qiao
Y, Hu Y, Lu W, Zhou Z, Xu P and Zhou Q: Triptonide effectively
inhibits triple-negative breast cancer metastasis through
concurrent degradation of Twist1 and Notch1 oncoproteins. Breast
Cancer Res. 23:1162021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Yang D and Zhang QF: The natural source,
physicochemical properties, biological activities and metabolism of
astilbin. Crit Rev Food Sci Nutr. 63:9506–9518. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Sharma A, Gupta S, Chauhan S, Nair A and
Sharma P: Astilbin: A promising unexplored compound with
multidimensional medicinal and health benefits. Pharmacol Res.
158:1048942020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Wang Y, Gu Y, Liu Q, Ma S and Gong Z:
Astilbin inhibits proliferation, migration and vasculogenic mimicry
formation of breast cancer cells by regulating HIF-1α/VEGF axis.
Chin J Cancer Biother. 31:796–802. 2024.(In Chinese).
|
|
103
|
Haq S, Ali S, Mohammad R and Sarkar FH:
The complexities of epidemiology and prevention of gastrointestinal
cancers. Int J Mol Sci. 13:12556–12572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Maloney S, Clarke SJ, Sahni S, Hudson A,
Colvin E, Mittal A, Samra J and Pavlakis N: The role of diagnostic,
prognostic, and predictive biomarkers in the management of early
pancreatic cancer. J Cancer Res Clin Oncol. 149:13437–13450. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zhang Z, Zhou N, Guo X, Li N, Zhu H and
Yang Z: Pretherapeutic assessment of pancreatic cancer: Comparison
of FDG PET/CT plus delayed PET/MR and contrast-enhanced CT/MR.
Front Oncol. 11:7904622022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Del Chiaro M, Sugawara T, Karam SD and
Messersmith WA: Advances in the management of pancreatic cancer.
BMJ. 383:e0739952023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Benjakul N, Prakobphol N,
Tangshewinsirikul C, Dulyaphat W, Svasti J, Charngkaew K and
Kangsamaksin T: Notch signaling regulates vasculogenic mimicry and
promotes cell morphogenesis and the epithelial-to-mesenchymal
transition in pancreatic ductal adenocarcinoma. PLoS One.
17:e02790012022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhao T, Wang Z and Lin S: Inhibitory
effect of ginsenoside Rg3 on vasculogenic mimicry in pancreatic
cancer. Chin J Trad Chin MedPharm. 39:5509–5513. 2024.
|
|
109
|
Cai X, Wang Z, Lin S, Chen H and Bu H:
Ginsenoside Rg3 suppresses vasculogenic mimicry by impairing
DVL3-maintained stemness via PAAD cell-derived exosomal miR-204 in
pancreatic adenocarcinoma. Phytomedicine. 126:1554022024.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhao T, Wang Z and Lin S: Ginsenoside Rg3
inhibits epithelial-mesenchymal transition and vasculogenic mimicry
of pancreatic cancer cells through PI3K signaling. Chin Trad Herbal
Drugs. 55:6261–6268. 2024.(In Chinese).
|
|
111
|
Pandiar D, Smitha T and Krishnan RP:
Vasculogenic mimicry. J Oral Maxillofac Pathol. 27:228–229. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Tian X, Si Q, Liu M, Shi J, Zhao R, Xiong
Y, Yu L, Cui H and Guan H: Advance in vasculogenic mimicry in
ovarian cancer (Review). Oncol Lett. 26:4562023. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Lim D, Do Y, Kwon BS, Chang W, Lee MS, Kim
J and Cho JG: Angiogenesis and vasculogenic mimicry as therapeutic
targets in ovarian cancer. BMB Rep. 53:291–298. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Wang N, Yang Y, Wang H, Li Y, Wang M and
Li Q: Cinobufagin modulates vasculogenic mimicry and
tumor-associated macrophages to inhibit ovarian cancer progression.
Eur J Pharmacol:. 987:1771572025. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wang XY, Zeng HQ and Hu W: Cinobufagin
alleviates bone cancer pain by inhibiting the spinal CCL2/CCR2
pathway and microglial activation. Acta Pharmaceutica Sinica.
55:67–73. 2020.(In Chinese).
|
|
116
|
Farhan M: Green tea catechins: Nature's
way of preventing and treating cancer. Int J Mol Sci. 23:107132022.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Sicard AA, Dao T, Suarez NG and Annabi B:
Diet-derived gallated catechins prevent TGF-β-mediated
epithelial-mesenchymal transition, cell migration and vasculogenic
mimicry in chemosensitive ES-2 ovarian cancer cells. Nutr Cancer.
73:169–180. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Jiang S, Li S, Pang S, Liu M, Sun H, Zhang
N and Liu J: A systematic review: Sinomenine. Heliyon.
10:e299762024. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zhenyu Yan, Meng Guo, Ran Yang, Bo Su and
Haiyan Zhang: Effects of Sinomenine regulating CXCR4-STAT3 axis on
proliferation, migration and angiogenic mimicry of ovarian cancer
A2780 cells. J Mod Oncol. 32:2944–2951. 2024.
|
|
120
|
Zhou TJ, Huang XH, Gong L and Xiang L:
Vasculogenic mimicry and hypoxia-inducible factor-1α expression in
cervical squamous cell carcinoma. Genet Mol Res.
15:150173962016.PubMed/NCBI
|
|
121
|
Tang H, Chen L, Liu X, Zeng S, Tan H and
Chen G: Pan-cancer dissection of vasculogenic mimicry
characteristic to provide potential therapeutic targets. Front
Pharmacol. 15:13467192024. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Sun J, Tian Z, Wu J, Li J, Wang Q, Huang S
and Wang M: Pristimerin exerts pharmacological effects through
multiple signaling pathways: A comprehensive review. Drug Des Dev
Ther. 18:1673–1694. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Jianwei Luo, Hongke Huang and Yanli Hu:
Effects of pristimerin on the proliferation, apoptosis and
vasculogenic mimicry of cervical cancer HeLa cells by regulating
the Shh/Gli1 signaling pathway. Chin J Cancer Biother. 31:687–693.
2024.(In Chinese).
|
|
124
|
Chen C, Zhang QW, Ye Y and Lin LG:
Honokiol: A naturally occurring lignan with pleiotropic
bioactivities. Chin J Nat Med. 19:481–490. 2021.PubMed/NCBI
|
|
125
|
Xiaocong Jiang, Xiuhua Pan, Wenjuan Cai,
Chi Zhang and Yuhong Lan: Effects of honokiol on vasculogenic
mimicry and epithelial-mesenchymal transition of cervical cancer
cells. World Clinical Drug. 44:922–932. 2023.
|
|
126
|
Li Y, Hou M, Lu G, Ciccone N, Wang X and
Zhang H: The prognosis of anti-angiogenesis treatments combined
with standard therapy for newly diagnosed glioblastoma: A
meta-analysis of randomized controlled trials. PLoS One.
11:e01682642016. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Hujanen R, Almahmoudi R, Karinen S, Nwaru
BI, Salo T and Salem A: Vasculogenic mimicry: A promising
prognosticator in head and neck squamous cell carcinoma and
esophageal cancer? A systematic review and meta-analysis. Cells.
9:5072020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Peng D, Qiao HZ, Tan HY, Wang YX, Luo D,
Qiao LJ, Cai YF, Zhang SJ, Wang Q and Guan L: Ligustilide
ameliorates cognitive impairment via AMPK/SIRT1 pathway in vascular
dementia rat. Metab Brain Dis. 37:1401–1414. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hao K, Wang X, Liu Z, Liu D and Li J:
Effects of ligustilide regulating RhoA/ROCK signaling pathway on
biological behavior of esophageal cancer cells. Tianjin Medical
Journal. 52:1164–1170. 2024.(In Chinese).
|
|
130
|
Li B, Mao X, Wang H, Su G, Mo C, Cao K and
Qiu S: Vasculogenic mimicry in bladder cancer and its association
with the aberrant expression of ZEB1. Oncol Lett. 15:5193–5200.
2018.PubMed/NCBI
|
|
131
|
Zhong W and Zhang Q: Atractylodin: An
alkyne compound with anticancer potential. Am J Chin Med.
52:1729–1757. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Lai H, Li Q, Lu Y, Liu Y, Qin X and Wei R:
Impacts of Atractylonin on Proliferation, Apoptosis and
Vasculogenic Mimicry of Bladder Cancer Cells by Regulating
RhoA/ROCK1 Signal Pathway. Chin J Cell Biol. 46:1497–1505. 2024.(In
Chinese).
|
|
133
|
Tímár J and Ladányi A: Molecular pathology
of skin melanoma: Epidemiology, differential diagnostics, prognosis
and therapy prediction. Int J Mol Sci. 23:53842022. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Zhang Z, Imani S, Shasaltaneh MD,
Hosseinifard H, Zou L, Fan Y and Wen Q: The role of vascular
mimicry as a biomarker in malignant melanoma: A systematic review
and meta-analysis. BMC Cancer. 19:11342019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Liu K, Zhang X, Xie L, Deng M, Chen H,
Song J, Long J, Li X and Lou J: Lupeol and its derivatives as
anticancer and anti-inflammatory agents: Molecular mechanisms and
therapeutic efficacy. Pharmacol Res. 164:1053732021. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Bhattacharyya S, Mitra D, Ray S, Biswas N,
Banerjee S, Majumder B, Mustafi SM and Murmu N: Reversing effect of
Lupeol on vasculogenic mimicry in murine melanoma progression.
Microvasc Res. 121:52–62. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Singh J, Trabulsi EJ and Gomella LG: Is
there an optimal management for localized prostate cancer? Clin
Interv Aging. 5:187–197. 2010.PubMed/NCBI
|
|
138
|
Kurganovs NJ and Engedal N: To eat or not
to eat: A critical review on the role of autophagy in prostate
carcinogenesis and prostate cancer therapeutics. Front Pharmacol.
15:14198062024. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Pender GC, Ombaka JH, Mwitari PG and Guyah
B: Common biological factors implicated in benign prostatic
hyperplasia and prostate cancer, conventional and phytotherapeutic
approaches employed in management: A review. Int J Sci Res Arch.
11:049–074. 2023. View Article : Google Scholar
|
|
140
|
Liu R, Yang K, Meng C, Zhang Z and Xu Y:
Vasculogenic mimicry is a marker of poor prognosis in prostate
cancer. Cancer Biol Ther. 13:527–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Yeo C, Han DS, Lee HJ and Lee EO:
Epigallocatechin-3-gallate suppresses vasculogenic mimicry through
inhibiting the twist/VE-Cadherin/AKT pathway in human prostate
cancer PC-3 cells. Int J Mol Sci. 21:4392020. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Nejabati HR and Roshangar L: Kaempferol: A
potential agent in the prevention of colorectal cancer. Physiol
Rep. 10:e154882022. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Da J, Xu M, Wang Y, Li W, Lu M and Wang Z:
Kaempferol promotes apoptosis while inhibiting cell proliferation
via androgen-dependent pathway and suppressing vasculogenic mimicry
and invasion in prostate cancer. Anal Cell Pathol (Amst).
2019:19076982019.PubMed/NCBI
|
|
144
|
Ren B, Kwah MX, Liu C, Ma Z, Shanmugam MK,
Ding L, Xiang X, Ho PC, Wang L, Ong PS and Goh BC: Resveratrol for
cancer therapy: Challenges and future perspectives. Cancer Lett.
515:63–72. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Han DS, Lee HJ and Lee EO: Resveratrol
suppresses serum-induced vasculogenic mimicry through impairing the
EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3
cells. Sci Rep. 12:201252022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Dudley AC and Griffioen AW: Pathological
angiogenesis: Mechanisms and therapeutic strategies. Angiogenesis.
26:313–347. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Qin L, Ren Y, Chen AM, Guo FJ, Xu F, Gong
C, Cheng P, Du Y and Liao H: Peroxisome proliferator-activated
receptor γ ligands inhibit VEGF-mediated vasculogenic mimicry of
prostate cancer through the AKT signaling pathway. Mol Med Rep.
10:276–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Pinto MP, Sotomayor P, Carrasco-Avino G,
Corvalan AH and Owen GI: Escaping Antiangiogenic Therapy:
Strategies Employed by Cancer Cells. Int J Mol Sci. 17:14892016.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li
B, Zhang H, Shan B, Zhang C and Duan C: Vasculogenic mimicry in
carcinogenesis and clinical applications. J Hematol Oncol.
13:192020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Chen N, Jiang D, Shao B, Bai T, Chen J,
Liu Y, Zhang Z, Zhou Y, Wang X and Zhu Z: Anti-BVDV activity of
traditional Chinese medicine monomers targeting NS5B (RNA-Dependent
RNA Polymerase) in vitro and in vivo. Molecules. 28:34132023.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Hu Z, Wang X, Hu Q and Chen X: Exploring
the protective effects of herbal monomers against diabetic
retinopathy based on the regulation of autophagy and apoptosis: A
review. Medicine (Baltimore). 102:e355412023. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Lv D, Liu Y, Tang R, Fu S, Kong S, Liao Q,
Li H and Lin L: Analysis of clinical trials using anti-tumor
traditional Chinese medicine monomers. Drug Des Devel Ther.
18:1997–2020. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Li Z, Zhu J and Ouyang H: Research
progress of traditional Chinese medicine in improving hepatic
fibrosis based on inhibiting pathological angiogenesis. Front
Pharmacol. 14:13030122023. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Zheng T, Jiang T, Huang Z, Ma H and Wang
M: Role of traditional Chinese medicine monomers in cerebral
ischemia/reperfusion injury:a review of the mechanism. Front
Pharmacol. 14:12208622023. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Ye R, Zheng Y, Chen Y, Wei X, Shi S, Chen
Y, Zhu W, Wang A, Yang L, Xu Y and Peng J: Stable loading and
delivery of melittin with lipid-coated polymeric nanoparticles for
effective tumor therapy with negligible systemic toxicity. ACS Appl
Mater Interfaces. 13:55902–55912. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Ke M, Dong J, Wu R and Lv Y: The
inhibitory effect of Melittin-K1, a mutant of Melittin, on the
growth of human hepatocellular carcinoma cell line BEL-7402. Modern
Oncology. 27:2636–2641. 2019.(In Chinese).
|
|
157
|
Sui X, Han X, Chen P, Wu Q, Feng J, Duan
T, Chen X, Pan T, Yan L, et al: Baicalin Induces Apoptosis and
Suppresses the Cell Cycle Progression of Lung Cancer Cells Through
Downregulating Akt/mTOR Signaling Pathway. Front Mol Biosci.
28:6022822021. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Wang R, Wang C, Lu L, Yuan F and He F:
Baicalin and baicalein in modulating tumor microenvironment for
cancer treatment: A comprehensive review with future perspectives.
Pharmacol Res. 199:1070322024. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Cao H, Li J, Sun S, Fang J, Wang Y, Zhang
Y and Mao W: Pharmacodynamic Effect and Mechanism of Baicalein on
Lung Adenocarcinoma A549 cells. Chinese Journal of Experimental
Traditional Medical Formulae. 23:98–103. 2017.(In Chinese).
|
|
160
|
Deng X, Ruan X and Hao H: Study on matrix
sustained release tablets of brucine solid lipid nanoparticles.
Chinese Traditional and Herbal Drugs. 49:5298–5304. 2018.(In
Chinese).
|
|
161
|
Guan Q, Wang L, Liu Z, Feng Y, Wen M, Zhao
Y, Feng W and Lyu S: Cytotoxicity and Cellular Uptake Test of
Brucine-loaded Solid Lipid Nanoparticles. Chinese Journal of
Experimental Traditional Medical Formulae. 23:1–6. 2017.(In
Chinese).
|
|
162
|
Pellerino A, Bruno F, Soffietti R and Rudà
R: Antiangiogenic therapy for malignant brain tumors: Does it still
matter? Curr Oncol Rep. 25:777–785. 2023. View Article : Google Scholar : PubMed/NCBI
|
